List of Excipients in Branded Drug LORATADINE AND PSEUDOEPHEDRINE

Generic Drugs Containing LORATADINE AND PSEUDOEPHEDRINE

Company	Ingredient	NDC	Excipient
Walgreen Company	loratadine and pseudoephedrine	0363-0725	CALCIUM CARBONATE
Walgreen Company	loratadine and pseudoephedrine	0363-0725	CELLULOSE, MICROCRYSTALLINE
Walgreen Company	loratadine and pseudoephedrine	0363-0725	FERROSOFERRIC OXIDE
Walgreen Company	loratadine and pseudoephedrine	0363-0725	HYDROXYPROPYL CELLULOSE
Walgreen Company	loratadine and pseudoephedrine	0363-0725	HYPROMELLOSE

What are the Most Frequently-Used Excipients in LORATADINE AND PSEUDOEPHEDRINE?

# Of NDCs	Excipient
15	CALCIUM CARBONATE
15	CELLULOSE, MICROCRYSTALLINE
2	COLLOIDAL SILICON DIOXIDE
1	FERRIC OXIDE BLACK
14	FERROSOFERRIC OXIDE

# Loratadine and Pseudoephedrine Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Loratadine-pseudoephedrine is a mature OTC combination with limited active-ingredient exclusivity and substantial generic competition. Commercial value rests on formulation execution: 12-hour versus 24-hour release, tablet robustness, abuse-resistant packaging, dose convenience, and channel access. The strongest opportunities are private-label supply, differentiated extended-release tablets, regional products, and adjacent formats that preserve pseudoephedrine’s regulatory controls.

What is the commercial profile of loratadine and pseudoephedrine combinations?

Loratadine is a second-generation H1 antihistamine. Pseudoephedrine is an oral sympathomimetic decongestant. The combination treats allergic rhinitis with nasal congestion.

The principal U.S. reference products are:

Product type	Loratadine dose	Pseudoephedrine dose	Release period	Commercial role
Claritin-D 12 Hour	5 mg	120 mg	Approximately 12 hours	Twice-daily adult product
Claritin-D 24 Hour	10 mg	240 mg	Approximately 24 hours	Once-daily adult product
Generic equivalents	Same reference strengths	Same reference strengths	12 or 24 hours	Pharmacy, retail and private-label supply

Pseudoephedrine is generally supplied as pseudoephedrine sulfate in these products. The formulation challenge is to release loratadine promptly or predictably while controlling pseudoephedrine release over the intended dosing interval.

The market is mature. The main business risks are low unit pricing, retailer bargaining power, formulation similarity, pharmacy purchasing restrictions and pseudoephedrine inventory controls under the Combat Methamphetamine Epidemic Act of 2005.[1]

What excipients are used in loratadine-pseudoephedrine extended-release tablets?

The excipient system normally combines a direct-compression or granulation platform with a hydrophilic or matrix-based release-control system.

Public labeling for reference and generic products identifies excipient classes such as lactose, microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide and coating materials, although the exact composition varies by manufacturer.[2]

Functional excipient architecture

Formulation function	Candidate excipient classes	Strategic purpose
Diluent	Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate	Controls tablet weight, density and compressibility
Binder	Povidone, copovidone, hydroxypropyl cellulose	Improves granule strength and content uniformity
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid breakup of immediate-release portions
Release modifier	Hypromellose, ethylcellulose, methacrylate polymers	Controls pseudoephedrine diffusion and erosion
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force and tooling adhesion
Glidant	Colloidal silicon dioxide	Improves powder flow
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Protects the tablet and supports identification
Moisture-control aid	Low-moisture fillers, protective coating, desiccant packaging	Limits degradation, sticking and dissolution drift

The key design issue is excipient compatibility. Loratadine is poorly soluble in water, while pseudoephedrine sulfate is highly water soluble. A formulation that controls the soluble decongestant can unintentionally slow or destabilize loratadine release.

How should the excipient strategy be designed for 12-hour and 24-hour products?

12-hour formulation strategy

A 12-hour product can use a comparatively moderate release-control system. The typical commercial objective is:

• rapid onset of antihistamine activity;
• sustained pseudoephedrine release;
• consistent tablet performance across fed and fasted conditions;
• adequate mechanical strength for blister and bottle distribution.

A multilayer or compartmental tablet can separate loratadine from the pseudoephedrine matrix. This approach gives greater control over the immediate-release and extended-release portions but increases tooling, process validation and scale-up requirements.

A monolithic matrix tablet is less expensive to manufacture. It may be preferable for private-label products where cost and manufacturing simplicity outweigh maximum formulation differentiation.

24-hour formulation strategy

The 24-hour product requires tighter control of pseudoephedrine release. A hydrophilic matrix based on hypromellose or a comparable polymer can provide a diffusion-and-erosion mechanism. Polymer viscosity, particle size, compression force and tablet porosity materially affect dissolution.

The formulation should be assessed against:

• initial dose dumping;
• excessive release after hydration;
• incomplete pseudoephedrine release;
• sensitivity to agitation;
• fed-state acceleration;
• alcohol-related release changes;
• tablet splitting or crushing;
• stability-related dissolution drift.

A coating can improve handling and moisture protection but should not be treated as the primary release-control mechanism unless supported by dissolution and stability data.

Direct compression versus wet granulation

Direct compression lowers process complexity and can reduce cost. It requires consistent powder flow, segregation control and good content uniformity.

Wet granulation can improve density and reduce segregation between loratadine, pseudoephedrine sulfate and functional excipients. It introduces additional risks, including moisture exposure, drying variability and potential changes in polymorphic or particle characteristics.

For a high-volume generic, a practical development sequence is:

1. Screen direct-compression blends.
2. Evaluate a hydrophilic matrix with two or more polymer grades.
3. Use granulation only if segregation, flow or dissolution variability cannot be controlled.
4. Lock the formulation against discriminatory dissolution methods before scale-up.

What formulations are protected by patents or regulatory exclusivity?

The core active ingredients are old and widely available. Commercial protection therefore depends on formulation claims, manufacturing claims, device or packaging claims, trademarks and regulatory compliance rather than new-molecule exclusivity.

Patent estate

The original Claritin and Claritin-D patent positions are historical. Any core composition or controlled-release patent associated with the original products should be treated as expired or commercially weak unless a current jurisdiction-specific patent search shows an unexpired claim with relevant scope.

Potentially relevant patent categories include:

• controlled-release pseudoephedrine matrices;
• multilayer tablets;
• separate release zones for loratadine and pseudoephedrine;
• particle-size or granulation controls;
• taste-masked or orally disintegrating formats;
• abuse-deterrent packaging;
• manufacturing processes;
• stability-enhancing coatings.

A later entrant is more likely to obtain value from a narrow formulation patent than from a broad combination patent. Claims must distinguish the product through measurable features such as dissolution, polymer concentration, tablet architecture or manufacturing parameters.

Orange Book status

The Orange Book is principally relevant to approved prescription and certain approved drug products. OTC monograph products and many generic OTC combinations do not receive the same patent-certification framework as prescription NDAs.[3]

For loratadine-pseudoephedrine, a commercial launch assessment should separate:

• an OTC monograph pathway;
• an approved NDA or ANDA pathway;
• private-label or store-brand distribution;
• product-specific patents listed for an approved application;
• trademarks and trade dress.

The absence of a listed Orange Book patent does not eliminate formulation or process patents. It does reduce the likelihood that an entrant will face a conventional Paragraph IV dispute based solely on the marketed OTC combination.

When does loratadine-pseudoephedrine lose exclusivity?

The combination has effectively lost core market exclusivity. Loratadine and pseudoephedrine are established active ingredients, and multiple generic and store-brand products compete in U.S. commerce.

The practical exclusivity timeline is:

Milestone	Commercial implication
Original Claritin commercialization	Established loratadine brand franchise
Claritin-D launch	Added decongestant combination and extended-release positioning
Expiration of legacy active and formulation rights	Enabled generic entry
OTC monograph framework	Supports standardized nonprescription competition
Current market	Brand, generic and private-label products compete primarily on availability and price

New exclusivity could arise only from a qualifying new formulation, a new approved indication, pediatric development or another statutory pathway. Such protection would not automatically cover ordinary generic 12-hour or 24-hour equivalents.

Which companies are challenging the reference product?

Generic competition has historically come from companies supplying pharmacy, mass-retail and private-label channels. The relevant competitive set includes large generic manufacturers, contract manufacturers and retailer-owned brands.

Because the product is commonly sold under OTC conditions, competitive entry is not limited to a single ANDA challenger. A manufacturer can compete through:

• an approved generic application;
• an OTC monograph-compliant product;
• a private-label supply agreement;
• a regional pharmacy brand;
• a licensed store-brand platform.

The strongest commercial competitors are those able to maintain pseudoephedrine supply, satisfy retailer documentation requirements and operate within pharmacy sales controls.

What Paragraph IV challenges and litigation affect loratadine-pseudoephedrine?

No major current Paragraph IV litigation should be assumed for the basic loratadine-pseudoephedrine combination. The active ingredients and conventional dosage strengths are mature.

A Paragraph IV dispute would be more plausible for:

• a newly patented 24-hour release profile;
• an abuse-deterrent pseudoephedrine formulation;
• a novel multilayer tablet;
• a new delivery format;
• a product-specific manufacturing patent.

A generic applicant challenging a relevant listed patent could file a Paragraph IV certification under the Hatch-Waxman framework. The patent holder could then file suit, potentially triggering a 30-month stay for an eligible NDA-listed patent.[4]

Settlement agreements would require product-specific review. No settlement should be presumed for the basic OTC combination absent a documented patent dispute and regulatory filing.

What regulatory barriers apply to pseudoephedrine products?

Pseudoephedrine is the principal regulatory constraint.

Federal controls

The Combat Methamphetamine Epidemic Act imposes retail sales limits, purchaser identification requirements, logbook or electronic-record obligations and storage controls for covered pseudoephedrine products.[1]

The Drug Enforcement Administration and FDA requirements affect:

• inventory reconciliation;
• theft and diversion controls;
• retail custody;
• shipment documentation;
• product returns;
• online and mail-order sales;
• state-specific restrictions.

These requirements increase working capital and operational complexity. They also favor established suppliers with compliance infrastructure.

FDA pathway

A product may proceed through the applicable OTC monograph framework or an approved application route, depending on the formulation, labeling and product category. The FDA monograph for oral antihistamine and decongestant products is codified in 21 C.F.R. part 341.[5]

A materially novel formulation, new indication or nonstandard dosage form can require an NDA or other FDA interaction. An applicant should not assume that a formulation change remains within a simple monograph pathway.

Biosimilar risk

There is no biosimilar risk. Loratadine-pseudoephedrine is a small-molecule combination, not a biologic. Competition comes from generic drugs, OTC monograph products, private labels and alternative allergy-decongestant products.

How strong is the patent estate for loratadine-pseudoephedrine?

The patent estate is weak for the basic active combination and potentially moderate for a narrowly differentiated delivery system.

Asset type	Expected protection strength	Reason
Loratadine composition patent	Low for new entrants	Mature active ingredient
Pseudoephedrine composition patent	Low for new entrants	Mature active ingredient
Basic combination claim	Low	Broad prior art and generic competition
12-hour matrix formulation	Low to moderate	Scope depends on release profile and prior art
24-hour matrix formulation	Moderate if technically distinct	More difficult release-control target
Multilayer tablet	Moderate	Architecture can support narrower claims
Manufacturing process	Moderate	Useful where process parameters affect performance
Packaging and diversion control	Low to moderate	More likely commercial differentiation than exclusivity
Trade secret process	Moderate	Can protect know-how without blocking independent development

The most defensible intellectual-property strategy combines a narrow patent portfolio with undisclosed process parameters. The practical trade secret candidates include polymer preconditioning, granulation endpoint, compression force, coating weight, blend order and dissolution-control methods.

What commercial opportunities exist for excipient suppliers and drug manufacturers?

Private-label and contract manufacturing

Retailers need dependable supply of 12-hour and 24-hour products. A manufacturer with validated extended-release technology can compete for private-label contracts without owning a high-value consumer brand.

The strongest offering includes:

• multiple tablet strengths;
• common excipient platforms;
• validated dissolution equivalence;
• bottle and blister configurations;
• retailer-specific labeling;
• pseudoephedrine compliance support;
• redundant API and excipient sourcing.

Differentiated release performance

A formulation that reduces fed-state variability or improves tablet integrity may create a commercial advantage. The improvement must be measurable and relevant to the FDA quality target product profile.

Potential differentiation includes:

• reduced initial pseudoephedrine burst;
• stable release across pH conditions;
• lower sensitivity to compression variation;
• improved humidity stability;
• reduced tablet size at equivalent dose;
• better packaging durability.

Lower-cost excipient substitution

Replacing a premium polymer or specialized excipient can improve gross margin, but substitution creates regulatory and bioequivalence risk. The formulation should be evaluated through comparative dissolution, impurity, stability and scale-up studies.

A single-platform excipient system for both 12-hour and 24-hour products can reduce manufacturing complexity. The polymer level and compression conditions can then be adjusted by strength rather than creating separate technology platforms.

Packaging and controlled-access products

Because pseudoephedrine is subject to retail controls, packaging has commercial value. Unit-dose blister packs, tamper-evident cartons and controlled-access pharmacy packaging can support compliance and reduce diversion risk.

Packaging patents are unlikely to create broad market exclusivity, but packaging know-how can strengthen retailer relationships and reduce operational losses.

How does loratadine-pseudoephedrine compare with competing allergy products?

Product category	Congestion relief	Sedation profile	Regulatory burden	Commercial pressure
Loratadine alone	Limited for congestion	Generally low	Low	Strong generic competition
Loratadine-pseudoephedrine	Stronger nasal decongestant positioning	Generally low from loratadine, but pseudoephedrine has stimulant-related effects	High due to pseudoephedrine controls	Mature generic and private-label market
Cetirizine-pseudoephedrine	Comparable category positioning	Cetirizine may cause more drowsiness in some users	High	Competes on brand and consumer familiarity
Fexofenadine-pseudoephedrine	Comparable category positioning	Generally low	High	Premium-brand and generic competition
Intranasal steroid plus oral antihistamine	Different therapeutic profile	Varies by product	Lower pseudoephedrine burden	Substitution risk for chronic allergy users

Loratadine-pseudoephedrine remains commercially relevant where consumers prioritize oral congestion relief and once-daily dosing. Intranasal products and non-decongestant antihistamines limit long-term growth.

What generic launch scenarios exist?

Scenario 1: Commodity generic launch

The manufacturer launches a conventional 12-hour or 24-hour tablet with no meaningful formulation differentiation. The product competes on price, availability and retailer access. This is the lowest-risk strategy but has the weakest margin profile.

Scenario 2: Private-label platform

The manufacturer supplies multiple retailers using a common validated formulation. This can improve volume and manufacturing utilization but increases customer concentration risk.

Scenario 3: Formulation-differentiated launch

The applicant develops a new matrix, multilayer design or packaging system with technical claims. This offers stronger positioning but requires greater development spending and may trigger patent review.

Scenario 4: Regional or international launch

Countries differ materially in pseudoephedrine scheduling, OTC status, dose limits and combination-product rules. Geographic expansion requires country-specific regulatory and supply-chain analysis. A U.S. formulation cannot be assumed to transfer unchanged to Canada, the European Union, Latin America or Asia-Pacific markets.

What revenue exposure does the patent position create?

Revenue exposure is driven by volume and channel access rather than patent expiry. The basic product has no durable innovator-style exclusivity. A brand owner can still retain revenue through:

• consumer recognition;
• retail placement;
• pharmacy availability;
• trusted quality;
• package convenience;
• supply reliability;
• line extensions.

For a generic manufacturer, the principal financial risks are price erosion, retailer concentration, API shortages and pseudoephedrine compliance costs. For an excipient supplier, the opportunity is more stable when the excipient is embedded in a validated platform and supported by regulatory documentation.

Key Takeaways

• Loratadine-pseudoephedrine is a mature OTC combination with limited core patent protection.
• Commercial value is concentrated in 12-hour and 24-hour extended-release execution.
• Hypromellose and related matrix polymers are central candidates for pseudoephedrine release control.
• Loratadine-pseudoephedrine requires careful segregation, content-uniformity and dissolution development because loratadine and pseudoephedrine have different solubility profiles.
• Pseudoephedrine retail controls are a larger market barrier than active-ingredient patent rights.
• The most practical opportunities are private-label manufacturing, excipient-platform development, packaging compliance and technically differentiated extended-release tablets.
• Biosimilar risk is irrelevant; the competitive risks are generic entry, private-label substitution and alternative allergy therapies.
• New patent value would most likely come from a narrow formulation, process or packaging claim rather than a broad combination claim.

FAQs

Can loratadine and pseudoephedrine be formulated in a single immediate-release tablet?

Yes, but a single immediate-release tablet does not provide the same commercial profile as Claritin-D 12 Hour or 24 Hour. It may require more frequent dosing and would need separate regulatory and labeling assessment.

Which polymer is most suitable for a 24-hour pseudoephedrine tablet?

Hypromellose is a common starting point for hydrophilic matrix development. The optimal grade and concentration depend on tablet geometry, compression, drug loading, excipient particle size and dissolution targets.

Is pseudoephedrine sulfate interchangeable with pseudoephedrine hydrochloride?

The salts are not automatically interchangeable on a weight-for-weight basis. Salt selection affects molecular weight, dose calculations, hygroscopicity, solubility, tablet weight and regulatory equivalence.

Can a new excipient create market exclusivity for a loratadine-pseudoephedrine product?

An excipient alone rarely creates meaningful exclusivity. Protection is more plausible when the excipient is part of a novel formulation with defined performance characteristics and patentable technical results.

Are loratadine-pseudoephedrine products suitable for pediatric commercialization?

Pediatric development requires age-appropriate dosing, safety evaluation, dosage-form design and labeling compliance. Pseudoephedrine’s cardiovascular and central nervous system effects create additional pediatric risk considerations.

References

1. U.S. Congress. (2005). Combat Methamphetamine Epidemic Act of 2005, Title VII of the USA PATRIOT Improvement and Reauthorization Act of 2005.

2. U.S. National Library of Medicine. (n.d.). DailyMed: Loratadine and pseudoephedrine sulfate extended-release tablet labeling. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2015). Submitting patent information and certifications in an ANDA: Questions and answers. https://www.fda.gov/

5. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341